Clinical Trials Directory

Trials / Completed

CompletedNCT06064487

Renal Cell Arrest and Damage Biomarkers in Progression and Outcome of Septic AKI

Role of Renal Cell Arrest and Damage Biomarkers in Progression and Outcome of Sepsis Associated AKI

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
80 (actual)
Sponsor
Alexandria University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of the current study is to assess the predictive value of renal cell arrest biomarkers (urinary TIMP2 and IGFBP7), renal damage biomarkers (urinary KIM-1) and microscopic examination of urinary sediment in progression and outcome of sepsis associated AKI.

Detailed description

Acute kidney injury occurred in about 45-53% of patients with sepsis, and most septic AKI was mild or moderate AKI (KDIGO stage 1 or stage 2). However, previous study showed that up to 40% of these mild or moderate AKI would progress to more severe AKI (KDIGO stage 3), of which 30% required dialysis and the risk of death increased by 3-fold, as high as 70%. Therefore, early identifying patients at high risk for progressive AKI might help clinicians to enhance individualized monitoring and personalized management in patient with septic AKI, which might prevent or halt the ongoing renal injury and improve the outcome of patients with sepsis.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTrenal cell arrest and damage biomarkers assessmentmeasurement of TIMP2 and IGFBP7, KIM-1

Timeline

Start date
2023-10-01
Primary completion
2024-04-01
Completion
2024-06-01
First posted
2023-10-03
Last updated
2024-06-18

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06064487. Inclusion in this directory is not an endorsement.